共 50 条
Long-Term Efficacy and Safety of Paliperidone 6-Month Formulation: An Open-Label 2-Year Extension of a 1-Year Double-Blind Study in Adult Participants With Schizophrenia
被引:11
作者:
Najarian, Dean
[1
]
Turkoz, Ibrahim
[2
,8
]
Knight, R. Karl
Galderisi, Silvana
[3
]
Lamaison, Hector F.
[4
]
Zalitacz, Piotr
[5
]
Aravind, Suresh
[2
,7
]
Richarz, Ute
[6
]
机构:
[1] Janssen Sci Affairs LLC, Titusville, NJ USA
[2] Janssen Res & Dev LLC, Titusville, NJ USA
[3] Univ Campania Luigi Vanvitelli, Naples, Italy
[4] Natl Univ La Plata UNLP, Dept Psychiat, Buenos Aires, Argentina
[5] Gorlice Specialist Hosp, Psychiat Unit, Gorlice, Poland
[6] Cilag Int, Janssen Res & Dev, Gubelstr, Zug, Switzerland
[7] Dural Consulting LLC, St Petersburg, FL USA
[8] Janssen Res & Dev LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560 USA
关键词:
Long-term efficacy;
schizophrenia;
long-acting injectable;
open-label extension;
paliperidone palmitate 6-month;
ACTING INJECTABLE ANTIPSYCHOTICS;
PALMITATE;
RELAPSE;
REHOSPITALIZATION;
NONADHERENCE;
MEDICATION;
ADHERENCE;
PLACEBO;
D O I:
10.1093/ijnp/pyad028
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Background Paliperidone palmitate 6-month (PP6M) demonstrated noninferiority to paliperidone palmitate 3-month in preventing relapse in patients with schizophrenia in a phase 3 double-blind (DB) study (NCT03345342). Here, we report long-term efficacy and safety results from a 2-year single-arm, open-label extension (OLE; NCT04072575) of this DB study. Methods Participants who completed the DB study without relapse were enrolled and followed-up every 3 months up to 2 years. Participants received 4 PP6M gluteal injections (700/1000 mg eq.) at baseline, 6-month, 12-month, and 18-month visits. Efficacy endpoints included assessment of relapse, Positive and Negative Syndrome Scale total score, Personal and Social Performance score, and Clinical Global Impression-Severity scale change from baseline. Safety was assessed by treatment-emergent adverse events (TEAEs), physical examinations, and laboratory tests. Results Of 178 participants enrolled, 154 (86.5%) completed the OLE (mean age: 40.4 years, men: 70.8%; mean duration of PP6M exposure during OLE: 682.1 days). Overall, 7/178 (3.9%) participants relapsed between 20 and 703 days after enrolment. Mean (SD) changes from baseline to endpoint were as follows: Positive and Negative Syndrome Scale total score, 0.7 (8.22); Clinical Global Impression-Severity, 0.0 (0.51); and Personal and Social Performance Scale, 0.5 (7.47). Overall, 111/178 participants (62.4%) reported & GE;1 TEAE; most common (>5%) TEAEs were headache (13.5%) and increased blood prolactin/hyperprolactinemia (18.0%); 8/178 (4.5%) participants experienced serious TEAEs, and 6/178 (3.4%) participants withdrew due to TEAEs. No deaths were reported. Conclusions The relapse rate observed with PP6M during the 2-year OLE was low (3.9%). Clinical and functional improvements demonstrated in the DB study were maintained during OLE, and no new safety concerns were identified.
引用
收藏
页码:537 / 544
页数:8
相关论文
共 50 条